Global Companion Animal Cardiac Drugs Market 2026 – 2035

The companion animal cardiac drugs market size in the world is estimated to be USD 1.24 billion in the year 2025 and is expected to grow from USD 1.37 billion in 2026 to about USD 3.18 billion by 2035 with a CAGR of 8.8% between the years 2026 and 2035.

The growing world population of companion animals and the strengthening of the human-animal attachment that is elevating veterinary health care spending, the escalating rate of cardiac diseases in dogs and cats, especially in older pet populations, the proliferation of cardiac drug formulations sanctioned by veterinarians amid the landmark clinical trial findings, the progressive humanization of pet health care that is pushing owners to seek more advanced treatment of cardiac diseases in their pets and the steady and high market growth over the forecast period are all indicators of a sustained and strong market growth over the forecast period.

Market Highlight

• North America had most of the companion animal cardiac drugs market with a market share of 42% in 2025.

• Asia Pacific The region will have the highest growth of 12.1% during the period 2026-2035.

• By drug type, the diuretics segment was taking about 28% of the market share in 2025.

• By type of drug, the segment of positive inotropes is increasing with the highest CAGR of 11.4 percent between 2026 and 2035.

• By type of animal, the dogs segment gave the greatest market share of 74% in 2025 with the cats segment projected to grow at the greatest CAGR of 10.6% in the assumed period between 2026 and 2035.

• By disease indication, myxomatous mitral valve disease segment will have the largest market share of 38% in 2025, and the dilated cardiomyopathy segment will have the quickest CAGR growth of 9.8% between 2026 and 2035.

• By channel of distribution, the veterinary hospitals and clinics segment was able to acquire 61% of the market share in 2025.

Significant Growth Factors

The Companion Animal Cardiac Drugs Market Trends present significant growth opportunities due to several factors:

• Rising Companion Animal Population and Deepening Human-Animal Bond Driving Premium Veterinary Care Expenditure:

The long-term structural growth impetus to the growth of companion animal cardiac drug markets is the increase in the number and value of pets in the world (as more and more people keep pets), the spurt in pet adoption during the pandemic that has permanently increased the number of companion animals in the world, and the gradual cultural transformation of pets to family member status, which creates proportionate growth in the veterinary medical use of pets in terms of both diagnosis and long-term pharmaceutical treatment of cardiac diseases.

A 2023-2024 National Pet Owners Survey by the American Pet Products Association (APPA) found that some 66% of households in the United States, or 86.9 million households, owned a pet, which is an improvement on the 56% in 1988, showing that the number of households owning a pet has grown over several decades into a secular phenomenon. The worldwide companion animal population -including dogs and cats as the most prevalent species- is approximated at more than 470 million dog pets and 370 million cat pets across the globe in terms of the number documented by the World Animal Health Organization (WOAH), which is the target population to address the management of cardiac disease in companion animals.

The cultural value of the human-animal bond can be directly observed in the trends of veterinary healthcare expenditure: Americans spent about USD 38.3 billion on veterinary care in 2023 according to the American Pet Products Association, and the rate of increase in pet healthcare spending is consistently higher than the inflation rate in human healthcare in a majority of developed markets as the owners extend the parameters of care that they apply to their members of the human family to their pets. A survey of owners of pets by the American Animal Hospital Association (AAHA) revealed that more than 90% of pet owners identified their pets as a member of the family and over 50% said that they would give their pets advanced care no matter the price, a tendency of behavior that directly increases the prescription and long-term maintenance of cardiac drugs that represent monthly expenses of USD 50 to USD 400 per animal based on drug prescriptions and intricacy. The pet insurance business, which has removed economic obstacles to high-quality veterinary care such as specialist cardiology care and long-term medical drug coverage, has expanded quickly, with the North American Pet Health Insurance Association showing that more than 6.2 million pets were insured in North America in 2023, which, as compared to 2018, is three times higher than the approximate 2.8 million insured in 2018, with insured pet owners showing significantly higher rates of veterinary spending and treatment uptake.

• High Prevalence of Cardiac Disease in Aging Companion Animal Populations:

Cardiac disease is one of the most common chronic medical conditions of companion animals, where the epidemiological burden of cardiac disease is directly proportional to the age of companion animal populations which are reaching older age-related risks of cardiac disease due to the improvement of companion animal nutrition, preventive care and the overall management of companion animal health. Myxomatous mitral valve disease (MMVD) - this is the most widespread cardiac disease of the dog, having an estimated prevalence of 10% in all dogs presented to a veterinary practice in the Western world as reported in the published literature of veterinary cardiology, and it is much more prevalent in older dogs, to the point of afflicting most small and toy breeds older than 10 years of age. One genetic tendency to MMVD is the well-documented genetic predisposition of Cav King Charles Spaniards, with published literature indicating that almost all the breed will have some level of mitral valve disease by the age of 10 years - a breed-specific prevalence, which has led to extensive research investment and clinical trial activity in managing MMVD.

Dilated cardiomyopathy (DCM) - the second most common cardiac disease in dogs - is seen most commonly in large and giant breeds such as Doberman Pinschers, Irish Wolfhounds, and Great Danes, with publications of prevalence studies indicating DCM rates between 40 and 50% of Doberman Pinschers of 8 years old and older based on echocardiographic screening studies. Feline cardiac disease Feline hypertrophic cardiomyopathy (HCM), the most frequent cardiac disease in cats — is an estimated disease in 15% of the general cat population and as high as 26% in seemingly healthy cats brought to echocardiographic studies as published in the Journal of Veterinary Internal Medicine, and is a significant and highly undiagnosed disease burden in the cat population. This increasing age of companion animal populations, due to better veterinary nutrition, preventive medicine and disease control increasing life expectancy, is increasing the vulnerable population at risk of age related cardiac disease each year, a compounding epidemiological force of long-term cardiac drug demand that is not proportionate to pet population growth rates.

What are the Major Advances Changing the Companion Animal Cardiac Drugs Market Today?

• Pimobendan's Expansion into Pre-Clinical Disease Management Following EPIC Trial Evidence:

The seminal EPIC (Efficacy of Pimobendan in Dogs with Preclinical Mitral Valve Disease) clinical trial, which was published in the Journal of Veterinary Internal Medicine in 2016 and which is one of the most carefully conducted randomized controlled trials in veterinary cardiology history, showed that oral pimobendan in dogs with preclinical MMVD and cardiac enlargement delayed the progression of congestive heart failure by a median of 15 months over placebo-treated dogs, and was the first clinical trial of The results of the EPIC trial, which were later reproduced and expanded by the ACVIM (American College of Veterinary Internal Medicine) consensus guideline update of 2019 defining pimobendan initiation in dogs with defined cardiac enlargement criteria as a standard of care recommendation, radically broadened the group of dogs that could be treated with pimobendan, who were formerly considered as possessing established congestive heart failure, to the much larger group of dogs in the asymptomatic preclinical phase of MMVD with cardiac enlargement and this was a Pimobendan a benzimidazolepyridazinone derivative with both positive inotropic and vasodilatory (lusitropic) activity that raises cardiac contractility and decreases cardiac afterload is indicated in veterinary medicine as Vetmedin (Boehringer Ingelheim) as an oral tablet and chewable product, and has become the highest-selling companion animal cardiac medication in the world. The ongoing research of pimobendan application in the management of feline cardiac disease along with the subsequent DELAY study reflects the current growth of the evidence base of pimobendan use across the cardiac indications in companion animals, with feline HCM being one of the potential opportunities of significant market growth in the event that the ongoing clinical trials prove as effective as the canine MMVD results.

• Spironolactone and Novel Diuretic Combinations for Advanced Heart Failure Management: The accumulating evidence base in support of the use of combination diuretic therapy in the management of congestive heart failure in companion animals incorporating the use of spironolactone as both an aldosterone antagonist and potassium-sparing diuretic agent in combination with loop diuretic furosemide in the therapeutic diuretic backbone of heart failure management protocols is driving the increasing use of spironolactone The evidence supporting the clinical benefit of spironolactone was based on a clinical trial, QUEST (Quality of Life and Extension of Survival Time with Spironolactone in Dogs with Myxomatous Mitral Valve Disease), which was a prospective, multicentric, randomized, placebo-controlled clinical trial that showed that spironolactone supplemented with conventional therapy consisting of furosemide, pimobendan and ACE inhibitors significantly increased the time to cardiac death or serious cardiac event in the hearts of dogs with heart failure related Spironolactone preparations approved by veterinarians such as Prilactone (Ceva Santé Animale) in the European market and compounded spironolactone preparations in North America are increasingly being used as part of multi-drug protocols of heart failure management in the light of this evidence and are adding to increasing per-patient pharmaceutical expenditure on management of advanced cardiac diseases. Another active tract in clinical research is the exploration of the possibility of the replacement of furosemide by torsemide, a longer-acting loop diuretic with potentially better pharmacodynamic properties than furosemide in the long-term maintenance of natriuresis in heart failure, as an alternative to furosemide in the treatment of congestive heart failure in dogs.

• Veterinary Cardiology Specialty Service Expansion and Advanced Diagnostic Capability: The accelerating increase in the number of board-certified veterinary cardiology specialists service providers (through dedicated veterinary cardiology referral centers, multi-specialty veterinary hospitals, and the growing number of diplomates of the American College of Veterinary Internal Medicine (Cardiology Specialty) and European College of Veterinary Internal Medicine) is leading to a growing network of specialists practitioners who diagnose cardiac diseases at earlier and more precisely defined disease stages and implement evidence-based treatment modalities that include full card In the past ten years, the number of ACVIM Cardiology Specialty diplomates in North America has increased by more than 400 in 2024 compared to about 200 in 2010, which is a doubling of the workforce of specialist cardiology compared to the 2010s, which increased geographic presence of specialist cardiac care outside of major metropolitan areas to suburban and regional veterinary referral markets. State-of-the-art high-quality cardiac diagnostic technology such as portable echocardiography services that provide the capability to do point-of-care cardiac imaging in general practice areas, NT-proBNP (N-terminal pro-B-type natriuretic peptide) cardiac biomarker tests that provide the ability to do non-invasive screening of cardiac disease in at-risk animals, and Holter monitoring that provides the ability to monitor ambulatory arrhythmia is facilitating earlier and more accurate diagnosis of cardiac disease in companion animals. Published market analyses of the global veterinary diagnostics market had an estimated value of USD 4.2 billion in 2023, and cardiac-specific diagnostic capability is an increasingly important portion of veterinary diagnostic investment - each diagnosis is a prospective long-term cardiac drug management case yielding a recurring pharmaceutical revenue over the balance of the decades-long life of the diagnosed animal.

Category Wise Insights

By Drug Type

Why Do Diuretics Lead the Companion Animal Cardiac Drugs Market?

Diuretics will be the most prominent type of drug market segment that will constitute about 28% of the market share in 2025. The role of diuretics as the cornerstone and the indispensable aspect of the therapy of congestive heart failure - the clinical outcome of most progressive cardiac diseases in companion animals, where improvement of fluid overload through renal sodium and water excretion is the most life-saving and symptomatic therapeutic intervention in existence—is manifested by this domination. Furosemide loop diuretic- this is a diuretic that blocks the Na-K-2Cl cotransporter along the thick ascending limb of the Henle — is the most common and most extensively prescribed cardiac medication in companion animal practice worldwide, being available in oral tablet, oral liquid and injectable dosage forms in branded and generic form by a variety of manufacturers and used at the spectrum of cardiac disease severity between mild volume overload and acute pulmonary edema necessitating emergency intravenous treatment. The ubiquitous nature of furosemide in the management of congestive heart failure (where almost all dogs and cats with CHF that are treated with medical management will receive furosemide as a staple of their treatment) and the low unit cost of manufacturing furosemide and, hence, the prevalence of generic furosemide in the marketplace have helped the diuretics to stay at the head of volume in the cardiac drug category despite the entrance of newer agents such as pimobendan into the market generating greater unit revenues. Total diuretic category revenue is growing due to the increased use of spironolactone in the advanced treatment of CHF, which is becoming more commonly used in veterinary medicine as a combination of furosemide and spironolactone. The market stability of the diuretic segment is further supported by the clinical fact that congestive heart failure patients are expected to increase the diuretic doses as the disease progresses over time creating the per-patient diuretic spending throughout the cardiac disease management lifecycle.

By Animal Type

Why Do Dogs Dominate the Companion Animal Cardiac Drugs Market?

Dogs are the most overwhelmingly dominant type of animal in the market, with an estimated 74% of total market share in 2025, as canine cardiac disease is far more pharmacologically aggressively managed than feline cardiac disease due to its higher prevalence in the canine population, the established evidence base that supports multi-drug cardiac management regimens in the dog population through rigorous clinical trials such as EPIC, QUEST and IMPROVE-CHF; and the higher average weight of a dog that necessitates an equally greater drug dose and consequently incurs a higher per The variety of cardiac diseases affecting dogs including MMVD in small breeds, DCM in large breeds, arrhythmogenic right ventricular cardiomyopathy in Boxer dogs, infective endocarditis, pericardial disease and congenital cardiac defects produce a breadth of drug class requirements, including diuretics, positive inotropes, ACE inhibitors, antiarrhythmics, and beta-blockers that creates a multi-drug market with a wide spectrum of products across the dog population. The fact that the average lifespan of dogs living with veterinary care would be longer than the average lifespan of cats, as well as the progressive nature of cardiac disease requiring higher and higher amounts of drugs over time, would imply that every case of cardiac disease in dogs would be a multi-year course of pharmaceutical management with annual increases in drug costs as the disease progresses through the stages of ACVIM staging.

By Disease Indication

Why Does Myxomatous Mitral Valve Disease Lead the Market?

MMVD is the biggest disease indication segment with about 38% market share total in 2025, indicating its prevalence as the most frequent cardiac disease in dogs, or about 75–80% of all cardiac disease cases in canine patients as documented in the veterinary cardiology literature, and the intensive management of the disease using drugs through various disease stages, including preclinical enlargement to congestive heart failure. The ACVIM consensus-based MMVD management - defining pimobendan use in Stage B2 (preclinical MMVD with cardiac enlargement) and the combination of multiple drugs in Stage C (congestive heart failure), incorporating pimobendan, furosemide, and an ACE-inhibitor into a standard three-drug regimen - forms a structured guideline-based system of pharmaceutical management providing significant and predictable drug use in all of the large MMVD patient group. Breed-specific predispositions of MMVD to Cavalier King Charles Spaniels, Dachshunds, Chihuahuas, Miniature Poodles and many other popular companion dog breeds in North America, Europe, and Asia Pacific make MMVD treatment the leading cardiac drug indication in literally every major companion animal market in the world. The MMVD segment will also be distinguished by the longest average duration of pharmaceutical management of all cardiac disease indications - with dogs of Stage B2 having a potential to be treated with pimobendan potentially over many years before the development of heart failure, and Stage C having the potential to be treated over months to years potentially depending on the severity of the disease - realizing a high level of lifetime drug revenue per diagnosis.

By Distribution Channel

Why Do Veterinary Hospitals & Clinics Dominate?

Veterinary hospitals and clinics are the greatest distribution channel, with a 61% market share in 2025, due to the prescription-only regulatory status of cardiac drugs in companion animal medicine, such as pimobendan, furosemide, enalapril, atenolol, and practically all cardiac medications, which demand veterinary examination, identification, and prescription issuance prior to dispensing, which makes the veterinary practice the compulsory access point to cardiac drugs in all the major markets. Veterinary hospitals and clinics both conduct cardiac diagnostic assessments and prescribe or dispense cardiac drugs, combining the diagnostic and pharmaceutical pathways within one clinical interaction that strengthens in-practice dispensing of drugs as the deductive route of cardiac drug dispersion. Veterinary cardiology referral centers.

Veterinary cardiology referral centers, which have board-certified cardiologists to perform echocardiographic examinations, electrocardiography, Holter monitoring, and full cardiac staging, begin complex multi-drug cardiac regimens and have the highest volume of cardiac drug prescription per patient, as cardiologists tend to prescribe more complex and guideline-based dosages than when dealing with patients in general practice. Online veterinary pharmacies constitute the most rapidly expanding distribution channel with an estimated CAGR of 16.8% between 2026 and 2035, owing to the convenience of home delivery of long-term cardiac medication refills in companion animals undergoing the indefinite chronic use of cardiac medications, including furosemide and enalapril, the competitive pricing that online veterinary pharmacies face to provide when compared to in-clinic medication dispensing; and the communication of online pharmacies with the veterinary electronic medical record systems so that prescription transmissions and refill authorization workflows are streamlined.

Report Scope

Regional Analysis

How Big is the North America Market Size?

The North America companion animal cardiac drugs market size is estimated at USD 521 million in 2025 and is projected to reach approximately USD 1.27 billion by 2035, with a CAGR of 9.3% from 2026 to 2035.

Why Did North America Dominate the Market in 2025?

In 2025 about 42% of the global market share is in North America, reflecting the fact that the United States is the largest companion animal healthcare market in the world in terms of spending, the number of board-certified veterinary cardiologists, and the provision of a specialized level of care based on current background regulations, as well as the concentration of the leading veterinary pharmaceutical companies such as Boehringer Ingelheim Animal Health (headquarters, North America) with its commercial portfolio of cardiac drugs, Elanco Animal Health and Zoetis, the latter with its commercial cardiac drug and High population of small and toy breed dogs in the United States. — also having the popular breeds of Cavalier King Charles Spaniards, Chihuahuas, Dachshunds, and Miniature Poodles is a large at-risk group for MMVD and creates endemic demand for pimobendan and combination heart failure therapies. Practice Guidelines of cardiovascular disease by small animals produced by the AAHA, much followed as the clinical standard of care reference guide by North American general practice veterinarians, have served to disseminate specialist cardiology evidence and treatment protocols into the general practice environment, where it has increased the application of evidence-based cardiac drugs to the much larger general practice patient population.

Why is Europe a Strategically Critical Market?

The European companion animal cardiac drugs market is already approximated to be USD 372 million in 2025 and is estimated to grow to around USD 880 million in 2035 with a CAGR of 9.0%. Europe is a market of great significance due to the high concentration of Cavalier King Charles Spaniels and other MMVD-prone breeds in the United Kingdom, where the Cavalier King Charles Spaniel is the most popular dog breed, France, Germany, and Scandinavia, which create endemic MMVD drug demand, and a network of cardiology specialists joining forces creating evidence-based practice adoption within European veterinary cardiology. The veterinary medicines evaluation system designed by the European Medicines Agency to meet marketing authorization of veterinary cardiac drug marketing requires detailed quality, safety and efficacy dossiers which enable veterinarians to be assured of the quality of their prescribing decisions and justify premium pricing of completely authorized veterinary cardiac products. The United Kingdom has a historic constitutive powerful breeding and ownership base, the Cavalier King Charles Spaniel; coupled with the near-universal predisposition of the breed to MMVD, the United Kingdom is amongst the highest per-capita companion animal cardiac drug markets in the world.

Why is Asia Pacific the Fastest-Growing Market?

The fastest-growing regional market is Asia Pacific with a projected CAGR growth of 12.1% between 2026 and 2035, due to the booming growth of companion animal ownership in China, Japan, South Korea and Australia, especially among urban millennial and Gen Z consumers who are taking up companion animals as family members, the progressive development of specialized and referral-level veterinary cardiology services in larger Asian metropolitan areas, the rising penetration of pet health insurance in Japan and Australia reducing the financial barriers to advanced cardiac care, and increased awareness of evidence-based practices. In the Asia Pacific, Japan is the most commercialized veterinary pharmaceutical market with a well-developed veterinary healthcare system and a high expenditure on veterinary health care per capita, rivaling the Western European markets, as well as a high number of urban companion animals with well-developed specialist veterinary care. The ability of China to develop high-end veterinary medical services, as evidenced by a growth of corporate-owned veterinary hospital chains such as New Ruipeng Pet Healthcare Group that have begun to expand their specialty service offerings such as cardiology in larger cities, is offering new cardiac diagnosis and drug management infrastructure to benefit the newly emerging urban pet-owning middle class.

China Market Trends

The companion animal cardiac drugs market in China is at a fairly infantile commercial stage though with a massive growth rate, driven by the phenomenal growth of companion animal ownership in Chinese urban areas; the estimated number of dog and cat owners in China is among the largest in the world, the progressive establishment of specialist veterinary services in tier-one cities in China such as Beijing, Shanghai, Guangzhou and Shenzhen and the increasing availability of internationally registered veterinary cardiac drugs due to the changing veterinary drug regulatory framework administered by the Ministry of Agriculture and Rural Affairs. The growing readiness of Chinese pet owners to pay more money on high-quality veterinary care for their companion animals, which indicates the strong emotional attachment between urban Chinese consumers and their pets in the single-child family set up and the aging effect, is favoring the continued adoption of special cardiac assessment and long-term medication care by Chinese companion animal cardiac patients.

Why is the Middle East & Africa Region an Emerging Market?

The LAMEA region is an emerging companion animal cardiac drugs market, facilitated by the increasing urban companion animal ownership in the Gulf Cooperation Council, especially in the UAE and Saudi Arabia, due to existing expatriate and increasingly local populations with European and North American companion animal ownership norms; the establishment of multi-specialty veterinary hospitals in Dubai, Abu Dhabi, and Riyadh providing cardiological services to companion animals, including echocardiography; and a high companion animal population in Brazil and expanding veterinary drug markets in Australia and New Zealand, which encourage higher than average companion animal cardiac drug usage. The Brazilian market is the most significant amongst the LAMEA countries, and its companion animal population is huge and well-established with a veterinary pharmaceutical distribution network where internationally registered cardiac medication, such as pimobendan and furosemide, can be found.

Top Players in the Market and Their Offerings

• Boehringer Ingelheim Animal Health

• Elanco Animal Health Inc.

• Ceva Santé Animale

• Dechra Pharmaceuticals plc

• Zoetis Inc.

• Vetoquinol S.A.

• Norbrook Laboratories Ltd.

• Orion Corporation

• Anivive Lifesciences Inc.

• Bova Compounding (Australia)

• Kindred Biosciences (Elanco)

• Others

Key Developments

The market has experienced tremendous developments, with players in the industry aiming to increase their companion animal cardiac drug portfolio, improve clinical evidence in emerging indications, and market to the increasing global demand for evidence-based cardiac disease management regimens in companion animals.

• In October 2024: Boehringer Ingelheim Animal Health stated that it had enrolled its prospective, multicenter clinical trial in its study of pimobendan (Vetmedin) in cats with hypertrophic cardiomyopathy and systolic dysfunction - a trial that was expected to produce the species-specific regulatory quality efficacy and safety data needed to support a possible labeling expansion of Vetmedin into the feline HCM indication in the United States and in the European Union.

• In February 2025: Dechra Pharmaceuticals declared that the European Medicines Agency had accepted Cardisure Chewable Tablets - a palatable, liver-flavored chewable pimobendan preparation designed to enhance oral drug compliance in dogs with long-term cardiac medication needs in a novel, 1.25-mg tablet strength.

These strategic initiatives have enabled the companies to consolidate and increase market shares, augment the clinical evidence to support new indications and patient groups, create better formulations to increase medication adherence in long-term cardiac management, and invest in new mechanisms of therapy that are not covered by the existing standard-of-care pharmaceutical toolkit used by veterinary cardiologists and companion animal practitioners worldwide.

The Companion Animal Cardiac Drugs Market is segmented as follows:

By Drug Type

• Diuretics (Furosemide, Spironolactone, Torsemide, Hydrochlorothiazide)

• Positive Inotropes (Pimobendan, Digoxin)

• ACE Inhibitors (Enalapril, Benazepril, Ramipril, Imidapril)

• Beta-Blockers (Atenolol, Carvedilol, Metoprolol)

• Antiarrhythmics (Sotalol, Mexiletine, Amiodarone, Diltiazem)

• Calcium Channel Blockers (Amlodipine, Diltiazem)

• Aldosterone Antagonists

• Other Drug Types (Sildenafil, Omega-3 Supplements)

By Animal Type

• Dogs

• Cats

• Other Companion Animals (Ferrets, Rabbits)

By Disease Indication

• Myxomatous Mitral Valve Disease (MMVD)

• Congestive Heart Failure (CHF)

• Dilated Cardiomyopathy (DCM)

• Hypertrophic Cardiomyopathy (HCM — primarily feline)

• Cardiac Arrhythmias

• Systemic Hypertension with Cardiac Involvement

• Other Indications

By Distribution Channel

• Veterinary Hospitals & Clinics

• Retail Veterinary Pharmacies

• Online Veterinary Pharmacies

• Compounding Pharmacies

• Other Channels